1. The Present and Future Use of β-Blockers

   • N. M. Kaplan

   Section 1A: Hypertension 14 December 2012 Pages: 1 - 4

2. State-of-the-Art Review: β-Blockade and the Treatment of Hypertension

   • J. I. S. Robertson

   Section 1A: Hypertension 14 December 2012 Pages: 5 - 11

3. The Problem of Compliance with Antihypertensive Regimens

   • David L. Sackett
   • R. Brian Haynes
   • D. Wayne Taylor

   Section 1A: Hypertension 14 December 2012 Pages: 12 - 18

4. Ambulatory Blood Pressure and its Variability During Randomised Double-blind Administration of Atenolol, Metoprolol, Pindolol and Long Acting Propranolol in Subjects with Mild to Moderate Hypertension

   • J. S. Floras
   • M. O. Hassan
   • P. Sleight

   Section 1A: Hypertension 14 December 2012 Pages: 19 - 25

5. Dose and Duration of Reponse to β-Blockers in the Treatment of Hypertension

   • J. C. Petrie
   • T. A. Jeffers
   • J. Webster

   Section 1A: Hypertension 14 December 2012 Pages: 26 - 29

6. Comparison of Antihypertensive Efficacy of Atenolol, Oxprenolol and Pindolol at Rest and during Exercise

   • E. Ambrosioni
   • F. V. Costa
   • B. Magnani

   Section 1A: Hypertension 14 December 2012 Pages: 30 - 36

7. A Comparative Study Between 100mg Atenolol and 20mg Pindolol Slow-Release in Essential Hypertension

   • P. Greminger
   • H. Vetter
   • W. Vetter

   Section 1A: Hypertension 14 December 2012 Pages: 37 - 41

8. Atenolol Dose-Finding Studies

   • T. Ishizaki
   • Y. Oyama

   Section 1B: Hypertension 14 December 2012 Pages: 42 - 49

9. β-Blockers and Calcium Antagonists

   • F. R. Bühler
   • U. L. Hulthén
   • P. Bolli

   Section 1B: Hypertension 14 December 2012 Pages: 50 - 57

10. β-Blockers and Renin

    • A. Zanchetti
    • G. Leonetti
    • C. Sala

    Section 1B: Hypertension 14 December 2012 Pages: 58 - 63

11. Activation of Prejunctional β-Adrenoceptors by Adrenaline Acting as a Co-transmitter

    • M. J. Rand
    • H. Majewski
    • L.-H. Tung

    Section 1B: Hypertension 14 December 2012 Pages: 64 - 68

12. Hypertensive Patients Treated with Atenolol

    • I. Maistrello

    Short Communication 14 December 2012 Pages: 69 - 70

13. Atenolol Once Daily in Essential Hypertension

    • C. L. Alicandri
    • E. Agabiti-Rosei
    • G. Muiesan

    Short Communication 14 December 2012 Pages: 70 - 71

14. Atenolol in Orally Treated Diabetic Patients

    • L. Hausmann
    • K. M. Goebel

    Short Communication 14 December 2012 Pages: 71 - 73

15. Italian League Against Hypertension, and Italian Society of Non-Hospital Cardiologists Atenolol Multicentre Study

    • C. Fernandez

    Short Communication 14 December 2012 Pages: 73 - 74

16. 9 Years’ Experience with Atenolol in the Treatment of Hypertension

    • N. C. Henningsen

    Short Communication 14 December 2012 Pages: 74 - 75

17. Indonesian Multicentre Trial in Hypertension

    • T. Darmadji

    Short Communication 14 December 2012 Pages: 75 - 76

18. Antihypertensive Effect, at Rest and During Isometric Exercise, of Long Term Treatment with Atenolol

    • L. Corea
    • M. Bentivoglio
    • M. Provvidenza

    Short Communication 14 December 2012 Pages: 76 - 77

19. Blood Pressure Response during Isometric and Dynamic Exercise after Long Term Treatment of Essential Hypertension

    • M. Middeke
    • A. Burkhart
    • H. Holzgreve

    Short Communication 14 December 2012 Pages: 77 - 78

20. The Effect of Long Term Therapy for Essential Hypertension with Atenolol and Chlorthalidone on Carbohydrate Tolerance

    • M. Luque Otero
    • C. Fernandez Pinilla
    • A. Fernandez-Cruz

    Short Communication 14 December 2012 Pages: 78 - 80

21. Effect of Atenolol and Metoprolol on Exercise and Post-Exercise Pulse and Blood Pressure, 24 Hours after Administration

    • A. K. Scott
    • J. W. Rigby
    • H. G. Lovell

    Short Communication 14 December 2012 Pages: 80 - 81

22. A Comparison of Atenolol and Metoprolol Once Daily on Blood Pressure during Rest and Exercise

    • B. E. Karlberg
    • J.-H. Attenhög
    • K. P. Öhman

    Short Communication 14 December 2012 Pages: 82 - 83

23. A Comparison of Antihypertensive Treatment Atenolol Plus Bendrofluazide vs a Combination Tablet, ‘Tenoretic’

    • D. McAreavey
    • M. P. Robertson

    Short Communication 14 December 2012 Pages: 83 - 83

24. Single Dose Oral Atenolol for Urgent Blood Pressure Reduction

    • L. T. Bannan
    • D. G. Beevers

    Short Communication 14 December 2012 Pages: 84 - 84

25. Atenolol and Left Ventricular Hypertrophy

    • M. M. Ibrahim

    Short Communication 14 December 2012 Pages: 85 - 86

26. Atenolol in the Treatment of Elderly Hypertensive Patients

    • J. D. Summa

    Short Communication 14 December 2012 Pages: 86 - 87

27. Multicentre Trial of Treatment of Hypertension in the Elderly in Primary Care

    • J. R. Coope

    Short Communication 14 December 2012 Pages: 87 - 88

28. A Combination of Chlorthalidone (12.5mg) and Atenolol (50mg) in the Elderly

    • K. Siamopoulos
    • R. Wilkinson
    • K. Boddy

    Short Communication 14 December 2012 Pages: 88 - 90

29. Blood Pressure in Children and its Relevance to Adult Hypertension The Brompton Study

    • M. de Swiet
    • P. M. Fayers
    • E. A. Shinebourne

    Short Communication 14 December 2012 Pages: 90 - 91

30. State-of-the-Art: Comparative Pharmacology of the β-Adrenoceptor Blocking Drugs

    • David G. Shand

    Section 2A: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 92 - 99

31. Haemodynamic Effects of β-Blockers

    • Jay N. Cohn

    Section 2A: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 100 - 102

32. β-Adrenoceptor Blocking Drugs and Renal Blood Flow with Special Reference to the Elderly

    • K. O’Malley
    • W. G. O’Callaghan
    • E. O’Brien

    Section 2A: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 103 - 107

33. β-Blockers and Renal Function

    • D. J. Warren
    • D. G. Waller
    • J. McAinsh

    Section 2A: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 108 - 112

34. Effect of Liver Function on β-Blocker Kinetics

    • Eero A. Sotaniemi
    • R. Olavi Pelkonen
    • Markku Anttila

    Section 2A: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 113 - 120

35. Inhibition of Drug Metabolism by β-Adrenoceptor Antagonists

    • N. D. S. Bax
    • M. S. Lennard
    • H. F. Woods

    Section 2B: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 121 - 126

36. Influence of β-Receptor Antagonists on Pharmacokinetics of Cimetidine

    • W. Kirch
    • H. Spahn
    • E. Mutschler

    Section 2B: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 127 - 130

37. Stable Oral Availability of Atenolol Coadministered with Hydralazine

    • A. J. McLean
    • Doris Wilhelm
    • B. G. Heinzow

    Section 2B: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 131 - 135

38. Effect of Oxprenolol on the Pharmacokinetics and Pharmacodynamics of Hydralazine

    • Gabrielle M. Hawksworth
    • A. M. Dart
    • J. C. Petrie

    Section 2B: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 136 - 140

39. Effect of β-Blockade on the Pressor Response to Coffee plus Smoking in Patients with Mild Hypertension

    • Stephen Freestone
    • Lawrence E. Ramsay

    Section 2B: Pharmacodynamics, Pharmacokinetics and Drug Interactions 14 December 2012 Pages: 141 - 145

40. Renal Impairment in Hypertension Not Improved by Nadolol when Compared with Atenolol

    • Jane Mueller
    • M. J. Byrne
    • L. H. Opie

    Short Communication 14 December 2012 Pages: 146 - 146

41. Atenolol and Liver Function

    • D. Lebrec
    • B. Flouvat
    • C. Dupont

    Short Communication 14 December 2012 Pages: 147 - 147

42. Impaired Metabolism of Metoprolol in Poor Hydroxylators of Debrisoquine

    • M. S. Lennard
    • J. H. Silas
    • H. F. Woods

    Short Communication 14 December 2012 Pages: 147 - 148

43. Effects of Short and Long Term β-Blockade on Changes in Blood Pressure Caused by Cigarette Smoking in Normotensive and Hypertensive Subjects

    • C. Cuspidi
    • P. L. Aliprandi
    • L. Sampieri

    Short Communication 14 December 2012 Pages: 148 - 149

44. Cardiovascular Response to Cigarette Smoking during Adrenergic Block in Essential Hypertension

    • R. Fogari
    • A. Parini
    • G. Finardi

    Short Communication 14 December 2012 Pages: 149 - 150

45. Alcohol-induced Hypertension

    • D. G. Beevers
    • L. I. Bannan
    • J. F. Potter

    Short Communication 14 December 2012 Pages: 150 - 152

46. Interaction Between Alcohol and Metoprolol or Atenolol in Social Drinking

    • W. Kirch
    • H. Spahn
    • E. Mutschler

    Short Communication 14 December 2012 Pages: 152 - 152

47. β-Blockade for Angina and Arrhythmias

    • Stephen Scheidt

    Section 3: Angina and Arrhythmias 14 December 2012 Pages: 153 - 159

48. Atenolol in the Treatment of Angina Once Daily Cardioselective β-Blockade for Angina Pectoris

    • J. B. Schwartz

    Section 3: Angina and Arrhythmias 14 December 2012 Pages: 160 - 165

49. Cardioselectivity and Partial Agonist Activity in the Antianginal Efficacy of the β-Adrenoceptor Antagonists

    • B. Magnani
    • B. Mantovani
    • E. Ambrosioni

    Section 3: Angina and Arrhythmias 14 December 2012 Pages: 166 - 171

50. Atenolol in Unstable Angina

    • J. P. Godenir
    • M. Amor
    • A. Bertrand

    Section 3: Angina and Arrhythmias 14 December 2012 Pages: 172 - 176